In addition, osimertinib in combination with chemotherapy showed a significant advantage in prolonging PFS when compared with chemotherapy alone in patients with T790M mutation-positive NSCLC who had progressed on prior systemic therapy, including EGFR TKIs (66, 68). Here, EGFR is linked to non-small cell lung carcinoma.